Moreover, breast cancers from patients with aggressive subtypes (i.e., TNBC and HER2+) expressed higher levels of MXRA8 protein in primary tumors and metastatic lesions compared to less aggressive, ER+ breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.